Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as new therapies expand global market leadership.

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

The World Health Organization issued new guidance this week on the use of popular GLP-1 drugs, like Ozempic, Wegovy, Mounjaro ...

No matter what happens to the industry, though, there are plenty of excellent healthcare stocks that look attractive heading ...

Pharma companies need to move beyond the “weight-loss Olympics” and focus on more durable treatments with fewer side effects, ...

The obesity treatment space has been generating plenty of headlines – and sales – over the past few years. GLP-1 receptor ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The coming year, 2026, is shaping up as a critical operational and financial test. A head-to-head comparative study between Novo Nordisk's CagriSema and Eli Lilly's Zepbound, scheduled for 2026, will ...

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

By Maggie Fick LONDON, Dec 11 (Reuters) - Zealand Pharma plans to launch five obesity and related drugs by 2030 as the Danish ...

In this week’s edition of InnovationRx, Medline’s blockbuster IPO, Fred Moll’s surgical robotics investments, Forbes' ...